معرفی
Dr. Thomas Mark Conlon serves as Group Leader of the Immunopathology of COPD research team at the Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, Germany. Appointed to this leadership role in 2021 after joining as a Post-Doc in 2013, he directs investigations into immune mechanisms driving chronic lung disease within the Comprehensive Pneumology Center consortium.
His educational foundation includes a 2005 PhD from the University of Cambridge's Department of Pathology, where he studied immunoglobulin gene diversification, followed by seven years of postdoctoral research in Cambridge's Department of Surgery examining T/B cell interactions in chronic allograft rejection using heart transplant models. This translational trajectory culminated in his current focus on COPD immunopathogenesis.
Conlon's research program spans two interconnected domains: First, elucidating how adaptive immunity modulates tissue injury and regeneration in COPD, highlighted by his landmark Nature demonstration that LTβR blockade resolves tertiary lymphoid organs while reactivating WNT/β-catenin pathways to reverse emphysema. Second, investigating epigenetic drivers like PRMT7-mediated histone methylation in monocyte migration, revealing novel mechanisms of tissue injury in Nature Communications. His work consistently targets therapeutic reactivation of endogenous lung repair systems.
Publication trends reveal deepening exploration of immune-metabolic crosstalk (2023 oxysterol/SARS-CoV-2 study) and epigenetic regulation (2022 PRMT7 paper), with consistent focus on translating basic immunological discoveries into regenerative therapies for the world's third-leading cause of death.
His contributions have earned significant recognition:
- 2022 International Travel Scholarship Award from the American Thoracic Society
- 2018 Prize of Excellence in Lung Research at MLC/DZL symposium
- 2017 UHU Seed Funding Award from University of Western Australia
Securing competitive seed funding and international travel grants, Conlon's work bridges fundamental immunology and clinical translation. His lab maintains active collaborations within the Yildirim/Conlon research ecosystem, focusing on therapeutic targeting of lymphotoxin signaling and epigenetic modifiers.
The Conlon Lab operates within Helmholtz Munich's state-of-the-art facilities at the Comprehensive Pneumology Center, leveraging advanced mouse models, epigenetic profiling, and human tissue analysis to dissect immune mechanisms in chronic lung disease. Current efforts prioritize identifying druggable targets for reversing COPD progression through immune modulation.
